A team of Pillsbury lawyers has advised Sentynl Therapeutics, Inc. in its purchase of NULIBRY from BridgeBio Pharma, Inc. Sentynl, acquired by the Zydus Group in 2017, is a U.S.-based biopharmaceutical company focused on bringing innovative therapies to people living with rare diseases.

NULIBRY, medically termed fosdenopterin, is an FDA-approved injection used to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening pediatric genetic disorder.

According to BridgeBio and Sentynl’s press release, Sentynl will acquire global rights to NULIBRY and will be responsible for the ongoing development and commercialization of NULIBRY in the United States and developing, manufacturing and commercializing fosdenopterin globally.

The Pillsbury team was led by Corporate partners Christian Salaman and Jason Stirling and included Tax partner Brett Willis, Corporate associates Alex Graham and Kit Ryan, and senior legal analyst Rory O’Neill.